


angiogenesis with an effective amount of a compound which inhibits 14 kDa PLA<sub>2</sub>, and which has [The method according to Claim 1 wherein the compound is of] the formula:



wherein

R<sub>1</sub> is (CH<sub>2</sub>)<sub>n</sub>OH or (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sub>8</sub>;

n is 0 or an integer a value of 1;

X is oxygen or sulfur;

R<sub>2</sub> is hydrogen, halogen, optionally substituted C<sub>1-8</sub> alkyl, or C<sub>1-8</sub> alkoxy;

m is 0 or an integer having a value of 1 or 2;

R<sub>3</sub> is S(O)<sub>2</sub>R<sub>7</sub>;

R<sub>4</sub> is hydrogen or S(O)<sub>2</sub>R<sub>7</sub>;

R<sub>5</sub> is hydrogen, halogen, CF<sub>3</sub>, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>t</sub>C(O)R<sub>9</sub>, or (CH<sub>2</sub>)<sub>t</sub>OH;

t is 0 or an integer having a value of 1 or 2;

R<sub>6</sub> is hydrogen or halogen;

R<sub>7</sub> is optionally substituted aryl, optionally substituted arylC<sub>1-2</sub> alkyl, or an optionally substituted C<sub>1-8</sub> alkyl;

R<sub>8</sub> is hydrogen or C<sub>1-4</sub> alkyl;

R<sub>9</sub> is hydrogen or C<sub>1-4</sub> alkyl;

or a pharmaceutically acceptable salt thereof.

Please add the following claims:

7. A method of treating a chronic disease of diabetic retinopathy or ocular neovascularization in a mammal in need thereof, which disease is characterized by excessive, undesired or inappropriate angiogenesis with an effective amount of a compound which inhibits the production, transcription, translation or activity of 14 kDa PLA<sub>2</sub> and wherein the compounds were invented after the priority date of March 26, 1996.

8. A method of treating a chronic disease of tumor growth and metastasis in a mammal in need thereof, which disease is characterized by excessive, undesired or inappropriate angiogenesis with an effective amount of a compound which inhibits the